(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26±³À°ÀÏÀÚ : 2021-08-26
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : À±ÁöÇö
¿¬¶ôó : 070-4895-6129
À̸ÞÀÏ :
bmt@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-26 CH A 09:30~10:00 NGS-based MRD Monitoring Pre- and Post-Allogeneic HSCT for AML Michael Heuser(MHH Hospital)
±³À°½Ã°£ 08-26 CH A 10:00~10:30 Conditioning Intensity of Allogeneic Transplantation for AML with MRD Christopher S. Hourigan(NIH)
±³À°½Ã°£ 08-26 CH A 10:40~11:10 Engineering and Design for Next Generation CAR-T Cells Sham Mailankody(MSKCC)
±³À°½Ã°£ 08-26 CH A 11:20~11:50 Machine Learning Research for Hematopoietic Stem Cell Transplantation Yasuyuki Arai(Kyoto University)
±³À°½Ã°£ 08-26 CH A 11:50~12:20 Current Statistical Issues in Hematopoietic Cell Transplantation Haesook T. Kim(Dana-Farber Cancer Institute)
±³À°½Ã°£ 08-26 CH B 12:40~13:20 Optimizing Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Thomas Martin(University of California San Francisco)
±³À°½Ã°£ 08-26 CH A 13:30~14:30 Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants Eun Sang Yi(Korea University Guro Hospital)
±³À°½Ã°£ 08-26 CH A 14:40~15:10 High Throughput Single Cell Analysis in AML Koichi Takahashi(MDACC)
±³À°½Ã°£ 08-26 CH A 15:10~15:40 Therapeutic Implications in AML using Prospective Genomic Profiling Omar Abdel-Wahab(MSKCC)
±³À°½Ã°£ 08-26 CH A 15:40~16:10 Clonal Hematopiesis of Indeterminate Potential in Transplantation Kyoung Ha Kim(Soonchunhyang University Hospital)
±³À°½Ã°£ 08-26 CH A 16:30~17:00 FLT3 Inhibitor Maintenance Therapy after Allogeneic HSCT in FLT3 Mutated AML Richard T. Maziarz(Oregon Health and Science University)
±³À°½Ã°£ 08-26 CH A 17:00~17:30 Maintenance Therapy (Hypomethylating Agents, Bcl2-Inhibitor, Check Point Inhibitors, and Other Novel Drugs) after Allogeneic HSCT in AML and MDS Tapan Kadia(MDACC)
±³À°½Ã°£ 08-26 CH A 17:30~18:00 Treatment Strategies after Allogeneic HSCT in Relapsed ALL Ik-Chan Song(Chungnam National University College of Medicine)